RWell by RespondWellCheck Eligibility
    Tirzepatide treatment

    Weight Loss

    Weekly injection

    Tirzepatide

    Dual GIP/GLP-1 for powerful weight loss

    First order: $169

    Check Eligibility →Free provider review • You pay $0 if not approved

    Second and subsequent refills $229/per 30-day supply of medication or $349 for a 90-day supply of medication. Automatic refills – pause, delay or cancel anytime – just make those changes at least 48 hours before your next refill date.

    Prescription Required
    Doctor Prescribed
    100% Online
    UPS Next Day Air
    No Waiting Rooms
    No Membership Fees
    FSA/HSA Eligible
    Tirzepatide — everyday life

    Long days, short nights, the sleep you never caught up on — it adds up. Let's fix it.

    How it works

    Man on a video visit with a clinician from his phone at home

    Start

    Start from your phone

    Answer a few questions about your health and goals.

    ⏱ 5-10 minutes

    Video visit with a licensed clinician on a phone screen

    Review

    A clinician reviews your requested treatment

    They decide whether treatment is appropriate. No video visit required in 41 states.

    ⏱ <4 business hours

    Treatment box with medication ready to ship

    Delivered

    Your treatment ships

    One of our trusted pharmacy partners discreetly ships your medication to your doorstep.

    ⏱ <1 week*

    *Timelines shown reflect our average turnaround times and are not guaranteed.

    Tirzepatide treatment detail

    What Tirzepatide can do

    20.9% average weight loss in clinical trials.

    Tirzepatide is a groundbreaking dual GLP-1/GIP agonist that delivers superior weight loss results. Clinical studies demonstrate average weight loss of up to 20.9% of body weight over 72 weeks.

    Clinical outcomes based on published tirzepatide trials, including SURMOUNT-1 (weight loss)¹, SURPASS-2 (glucose & metabolic health)², SURPASS-4 (cardiovascular outcomes)³, and SURMOUNT-OSA (sleep apnea)⁴. Compounded versions of Tirzepatide are not associated with Eli Lilly & Company and/or its genuine MOUNJARO® and/or ZEPBOUND® products. Compounded versions of Tirzepatide are not FDA approved, and neither the FDA nor any global regulatory agency has reviewed these products for safety, quality, or efficacy. GLP-1s may cause serious side effects, including possible thyroid tumors, including cancer. See the 'Important Safety Information' links below for more details.

    Patients Love  RespondWell

    4.8 average. Patients love us. And we work hard to earn it.

    • Everything went as smoothly as possible. I was approved quickly, but it didn't feel like a rubber stamp. A real doctor reviewed everything and had some follow up questions for me. I had some questions a few weeks in and it was nice to still be able to message the prescriber.
      M.K. · Verified patient
    • RespondWell is on point. My meds showed up in less than three days, everything was nicely packaged, and the medication works well.
      S.T. · Verified patient
    • Fast and simple – exactly what I was looking for. The whole process was easy from start to finish.
      W.B. · Verified patient
    • This has worked tremendously well for me (and the wife). The fact that getting the treatment is so easy makes the whole experience that much better.
      N.C. · Verified patient
    • The sermorelin is awesome. Ordered on Sunday, got it by Wednesday. Sleeping like a baby.
      P.L. · Verified patient
    • They made everything pretty easy to understand, which I appreciated. Good experience overall and I've been happy with the care.
      T.M. · Verified patient
    • Honestly, everything has been easy. Good communication, good experience with the doctor, and no issues getting my medication.
      A.Z. · Verified patient
    • Couldn't have gone smoother. The doctor was fast, my medication was here within three days, and Joe was very responsive.
      J.W. · Verified patient
    • Very pleased so far. The whole experience has been easy and everything went exactly as expected.
      N.H. · Verified patient
    Your care team

    Meet the doctors

    Asad K. Niazi, MD, MPH
    Men's Health

    Asad K. Niazi, MD, MPH

    Internal Medicine (ABIM)

    Texas Tech University – Foster School of Medicine

    Shannon Arora, MD
    Longevity

    Shannon Arora, MD

    Family Medicine (ABFM)

    Xavier University School of Medicine

    Sean Arora, MD
    Longevity

    Sean Arora, MD

    Family Medicine (ABFM)

    Xavier University School of Medicine

    Abhishek Patel, DO
    Men's Health

    Abhishek Patel, DO

    Physical Medicine and Rehabilitation (ABPMR)

    Lake Erie College of Osteopathic Medicine

    Oversight

    Physician reviewed

    Dose

    Tirzepatide is administered as a once-weekly subcutaneous injection.

    Frequency

    Weekly injection

    Included

    Medication, supplies, expedited shipping

    Frequently Asked Questions

    Related treatments

    Semaglutide

    Semaglutide

    Semaglutide is a once-weekly injectable GLP-1 medication that has helped millions achieve lasting weight loss. It reduces appetite and helps you feel fuller longer.

    Starting at $110

    Learn more about Semaglutide

    Ready to Get Started?

    Check Eligibility for Tirzepatide

    *Clinical outcomes based on published tirzepatide trials, including SURMOUNT-1 (weight loss)¹, SURPASS-2 (glucose & metabolic health)², SURPASS-4 (cardiovascular outcomes)³, and SURMOUNT-OSA (sleep apnea)⁴. Compounded versions of Tirzepatide are not associated with Eli Lilly & Company and/or its genuine MOUNJARO® and/or ZEPBOUND® products. Compounded versions of Tirzepatide are not FDA approved, and neither the FDA nor any global regulatory agency has reviewed these products for safety, quality, or efficacy. GLP-1s may cause serious side effects, including possible thyroid tumors, including cancer. See the 'Safety Information' links below for more details.

    1 Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.

    2 Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515.

    3 Del Prato, S., Kahn, S. E., Pavo, I., et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet, 398(10313), 1811–1824.

    4 Malhotra, A., Grunstein, R. R., Gao, L., et al. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 391(13), 1193–1205.